The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.
Dendritic-cell (DC) targeted antigen delivery systems hold promise for enhancing vaccine efficacy and delivery of therapeutics. However, it is not known how the number and density of targeting ligands on such systems may affect DC function and subsequent T cell response. We modified the surface of biodegradable nanoparticles loaded with antigen with different densities of the mAb to the DC lectin DEC-205 receptor and assessed changes in the cytokine response of DCs and T cells. DEC-205 targeted nanoparticles unexpectedly induced a differential cytokine response that depended on the density of ligands on the surface. Strikingly, nanoparticle surface density of DEC-205 mAb increased the amount of anti-inflammatory, IL-10, produced by DCs and T cells. Boosting mice with DEC-205 targeted OVA-nanoparticles after immunization with an antigen in CFA induced a similar pattern of IL-10 response. The correlation between DC production of IL-10 as a function of the density of anti-DEC-205 is shown to be due to cross-linking of the DEC-205 receptor. Cross-linking also increased DC expression of the scavenger receptor CD36, and blockade of CD36 largely abrogated the IL-10 response. Our studies highlight the importance of target ligand density in the design of vaccine delivery systems.
Department of Biomedical Engineering, Yale University, PO Box 208260, New Haven, CT 06511, USA.
Arunima
A
Bandyopadhyay
Rebecca L
RL
Fine
Stacey
S
Demento
Linda K
LK
Bockenstedt
Tarek M
TM
Fahmy
D000818:Animals; D015703:Antigens, CD / Q000008:administration & dosage / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D005434:Flow Cytometry; D016753:Interleukin-10 / Q000378:metabolism; D037181:Lectins, C-Type / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018613:Microscopy, Confocal; D015778:Minor Histocompatibility Antigens; D053758:Nanoparticles / Q000737:chemistry*; D011956:Receptors, Cell Surface / Q000008:administration & dosage / Q000276:immunology*; D013601:T-Lymphocytes / Q000378:metabolism; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D015703:Antigens, CD; D016207:Cytokines; C093569:DEC-205 receptor; D037181:Lectins, C-Type; D015778:Minor Histocompatibility Antigens; D011956:Receptors, Cell Surface; D014612:Vaccines; D016753:Interleukin-10
Bioconjug Chem. 2008 Dec;19(12):2385-93
19053315
Trends Immunol. 2006 Dec;27(12):573-9
17049307
J Immunol. 2007 Sep 1;179(5):2797-807
17709493
Immunity. 2007 Dec;27(6):952-64
18093541
J Immunol. 2010 Sep 1;185(5):2989-97
20660705
J Immunother. 2007 May-Jun;30(4):378-95
17457213
Pharm Res. 2007 Oct;24(10):1834-43
17657598
Biomaterials. 2010 Feb;31(5):943-51
19850335
Nature. 2007 Sep 27;449(7161):419-26
17898760
Cell. 1990 Apr 20;61(2):203-12
2158859
J Pharm Pharmacol. 2004 Oct;56(10):1243-50
15482638
ACS Chem Biol. 2007 Apr 24;2(4):252-62
17432821
J Immunol. 2007 Mar 1;178(5):2979-86
17312143
Nature. 1998 Mar 19;392(6673):245-52
9521319
Nanomedicine. 2010 Oct;6(5):651-61
20348031
Blood. 2008 Aug 15;112(4):1231-9
18519810
Biotechnol Prog. 2008 Jul-Aug;24(4):807-14
19194892
J Immunol. 2003 Nov 1;171(9):4552-60
14568928
Mol Immunol. 2009 Mar;46(6):1229-39
19135256
J Exp Med. 1992 Dec 1;176(6):1693-702
1460426
Nanomedicine (Lond). 2008 Jun;3(3):343-55
18510429
J Biol Chem. 2002 Dec 20;277(51):49982-8
12376530
J Drug Target. 2009 Sep;17(8):662-70
19694614
Sci Signal. 2009 May 26;2(72):re3
19471024
J Am Chem Soc. 2002 Dec 18;124(50):14922-33
12475334
J Control Release. 2006 May 1;112(1):35-42
16516999
J Clin Invest. 2008 Apr;118(4):1427-36
18324335
Curr Top Microbiol Immunol. 2006;311:17-58
17048704
J Exp Med. 2004 Mar 15;199(6):815-24
15024047
J Exp Med. 2006 Mar 20;203(3):607-17
16505141
Vaccine. 2008 Sep 15;26(39):5046-57
18680779
Vaccine. 2006 May 8;24(19):4201-11
16446012
J Immunol. 2008 Mar 15;180(6):3647-50
18322168
Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422
15719481
Nanomedicine. 2009 Dec;5(4):410-8
19341815
Biomaterials. 2005 May;26(15):2713-22
15585275
Curr Opin Lipidol. 2000 Oct;11(5):483-91
11048891
Vaccine. 2009 May 18;27(23):3013-21
19428913
J Control Release. 2001 Sep 11;76(1-2):149-68
11532321
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1289-94
17229838
Eur J Pharm Biopharm. 2008 Jun;69(2):405-16
18364251
Vaccine. 2002 Nov 22;21(1-2):67-77
12443664
Mol Immunol. 2009 Dec;47(2-3):164-74
19818504
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18264-8
16344458
J Drug Target. 2003;11(8-10):495-507
15203918
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5
19139407
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 May-Jun;2(3):205-18
20391461
Trends Parasitol. 2003 Oct;19(10):461-9
14519584
Mol Ther. 2008 Apr;16(4):765-72
18334990
Immunobiology. 2006;211(6-8):599-608
16920498
J Cell Biol. 2000 Oct 30;151(3):673-84
11062267
J Drug Target. 2007 Dec;15(10):701-13
18041638
J Immunol. 2008 Mar 1;180(5):3201-9
18292544
J Biol Chem. 2002 Dec 6;277(49):47373-9
12239221
Biomaterials. 2005 Oct;26(28):5727-36
15878378